High-grade transformation of chronic lymphocytic leukaemia [Richter syndrome (RS)] is rare and represents a unique and uncommon clinical challenge. Clonally related diffuse large B cell type RS is a chemotherapy-resistant and devastating disease. Patients are typically elderly, immunosuppressed and present with a rapidly deteriorating performance status. Historical outcomes suggest a median overall survival of approximately 8 months. RS remains is an area of high unmet clinical need. The molecular profile and treatment needs of patients are likely to change over time with the advent of novel B cell receptor inhibitors, monoclonal antibodies and BH3 mimetics. Herein, we summarise what is known regarding the molecular drivers of RS and the existing clinical trial data, including the recently published CHOP-OR (cyclophosphamide, doxorubicin, vincristine, prednisolone and ofatumumab followed by ofatumumab maintenance in newly diagnosed RS) trial. We discuss novel agents in development with a focus on the second-generation Bruton tyrosine kinase inhibitor acalabrutinib, checkpoint inhibition and the potential role of precision medicine in future trials of RS.
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Background & definition
B cell chronic lymphocytic leukaemia (CLL) is the most common chronic lymphoproliferative disease. Infection, chemotherapy resistance and autoimmunity are frequent complications. In 1928, Maurice Richter was the first to describe an aggressive, life-threatening syndrome after a patient presented with rapidly fatal generalized lymphadenopathy and hepatosplenomegaly (Richter, 1928) . He described this 'reticular cell sarcoma' arising in a patient with known CLL. The term Richter syndrome was formally coined in the 1960s (Lotholary et al, 1964 ) and has subsequently been described as an aggressive lymphoma arising on the background of known CLL by the World Health Organisation (WHO) (Swerdlow et al, 2008) . The vast majority of patients with RS transform from CLL to activated B cell (ABC) type diffuse large B cell lymphoma (DLBCL), with a small minority transforming to classical Hodgkin lymphoma (cHL) (Bockorny et al, 2012) or other non-Hodgkin lymphomas (NHLs) including Burkitt lymphoma and lymphoblastic lymphoma. RS is typically characterised by an aggressive presentation, chemotherapy-resistance and very poor survival. Until recently there has been a relative paucity of data available regarding its pathogenesis, risk factors and optimal treatment.
Clinical presentation
Richter syndrome is typically suspected in a patient with known CLL who develops disproportionate weight loss, rapidly growing and/or asymmetrical lymphadenopathy or extranodal masses, new B symptoms, a rapidly rising lactate dehydrogenase (LDH) level or new hypercalcaemia. The biopsy typically displays a phenotype consistent with ABCtype DLBCL in 95% of cases of DLBCL. RS has a well described gene expression profile using microarray and is generally CD10 negative and FOXP1 and MUM1/IRF4 antigen positive by immunohistochemistry (IHC) (Choi et al, 2009; Rossi et al, 2011) .
Imaging with positron-emission-tomographycomputed tomography
In cases of suspected RS, fluorodeoxyglucose ([ 18 F] FDG) positron-emission-tomography (PET) computed tomography (CT) scanning has been proposed with the aim to biopsy the site of maximum standardized uptake value (SUV max ); particularly if the SUV max is high and asymmetric FDG-avidity is present. The median SUV max in CLL/small lymphocytic leukaemia, DLBCL, a cHL, and a secondary malignancy have been noted in a retrospective series of 90 patients as 3.5, 14.6, 7.0 and 6.3 respectively (P < 0.0001) (Mauro et al, 2015) . These data are consistent with a previously published series of 37 patients showing that using an SUV max cut-off of 5.0 could detect Richter transformation of CLL to DLBCL with a high sensitivity (91%) and a high negative predictive value (97%) (Bruzzi et al, 2006) . A prospective study of 44 patients confirmed these findings. The median SUV max was 3.4 (range 1.5-6.3) and 3.1 (range 1.2-5.9) in newly diagnosed and relapsed CLL, respectively whilst the median SUV max with suspected or confirmed RT reached 16.5 (range 7.2-25.3) (P < 0.001) (Papaj ık et al, 2014) . These studies were consistent with the prospective results from the recent prospective CHOP-OR (cyclophosphamide, doxorubicin, vincristine, prednisolone and ofatumumab followed by ofatumumab maintenance in newly diagnosed RS) trial . Within this trial, of the 17 patients with measurable disease on baseline PET-CT, the median SUV max was 18 (range 5.85-69.4). A large recent series aimed to correlate FDG/PET data, histological diagnosis and survival in patients with CLL (Falchi et al, 2014) . This was the first PET-based study to formally describe the term 'histologically aggressive CLL' (HAC), and was defined as the presence of expanded proliferation centres (broader than a 209 field) or high proliferation rate (either >2.4 mitoses/proliferation centre or Ki67 > 40%/proliferation centre). Patients with HAC (n = 117) and RS (n = 95) had a higher SUV max than typical CLL. An SUV max ≥10 was strongly associated with a higher mortality [overall survival (OS) 56.7 vs. 6.9 months for patients with SUV max <10 vs. ≥10] (Falchi et al, 2014) .
Risk factors for RS in the CLL
Retrospective data suggests the transformation rate ranges from 1% to 15% (Tsimberidou et al, 2006a; Rossi et al, 2008 Rossi et al, , 2011 . Data from the largest published data set (2001-10) from the Mayo Clinic (Parikh et al, 2013) has shown that RS arose in approximately 2-3% (37/1641) of CLL patients at a rate of approximately 0.5% per annum. Fortysix per cent of the patients from this study presented with RS without prior CLL treatment. A number of risk factors for the development of RS have been described. It has been consistently found that CLL patients with Rai stages III-IV disease and tumour bulk are at higher risk.
The backbone of CLL treatment over recent decades has been purine analogue and alkylator therapy. It is possible that these traditional chemotherapeutics increase the risk of RS transformation. The absolute increased risk is small, with the Mayo group describing a rate of 1% per annum for those treated versus 0.5% per annum for those not treated (Parikh et al, 2013) . The absolute risk of RS following chemotherapy is not completely consistent across the published literature.
Whether combining traditional chemotherapy increases the risk further has been debated. The large UK CLL4 trial and the Cancer and Leukemia Group B (CALGB) 9011 studies provide similar conclusions that prior chemotherapy does not consistently influence the RS transformation risk (Catovsky et al, 2007; Solh et al, 2012) . It is too early to be certain whether novel agents that target B cell receptor signalling, such as ibrutinib and idelalisib, or BCL2 inhibitors influence this risk. It is probable that the higher proportion of RS occurring after progression following agents such as venetoclax (Eichhorst et al, 2015; Roberts et al, 2015) and ibrutinib , is the result of the selection of resistant clones in relapsed, refractory CLL and a reflection of the disease biology of the patient cohorts treated rather than a causative effect. This will become clearer in the future, as these novel agents are used more frequently and earlier in the CLL treatment pathway.
There are several biological risk factors associated with progression of CLL to RS. Genetic defects, such as mutations and deletions of the genes TP53, CDKN2A (p16INK4A) or CDKN1A (p21) and loss of p27 expression, BCL2 overexpression, overexpression of CD38 and ZAP70, unmutated immunoglobulin heavy chain variable gene (IGHV), IGHV homology >98% and IGHV gene usage (B cell receptor subset 8 using IGHV4-39/IGHD6-13/IGHJ5) have been implicated in progression of CLL to RS across several studies (Rossi et al, 2008 ). The genotype and expression of CD38, the absence of del13q14 and the expression of IGHV4-39 are all independent risk factors for progression ).
Pathogenesis
Richter syndrome displays high genomic complexity. The acquisition of new genetic abnormalities result in the evolution of a more aggressive disease from CLL. Recent studies have highlighted some key genetic players as transforming events in the development of RS.
De novo disease
It is now known that approximately 20% of RS cases are derived from an unrelated clone to that of the underlying CLL (Rossi et al, 2011) . DLBCL and CLL clones may express the same surface light chain restriction and therefore sequencing of the IGHV gene from CLL and DLBCL tissue is more definitive. This subgroup is important to identify, as clonally-unrelated DLBCL have documented chemotherapy sensitivity and long term outcomes approaching that of de novo DLBCL without underlying CLL ). This subgroup possesses key molecular differences to clonally related RS, such as the significantly lower prevalence of TP53 disruption. The median OS for the clonally unrelated cohort in this large retrospective series was 62. compared to 14.2 months in clonally related RS (95% CI 7.7-20.6 months; P = 0.017). There is therefore a sound rationale to treat such clonally unrelated cases as de novo DLBCL. This explains the considerable heterogeneity of outcome in the RS literature, with cases of primary refractory disease and those still in complete remission (CR) 15 years later (Tsimberidou et al, 2006a) . It is debated whether clonally unrelated DLBCL should actually be classed as bona fide RS for the purpose of future clinical trial recruitment. To achieve this, real-time IGHV status analysis would be required from DLBCL tissue and prior or real time IGHV status would be needed from the circulating CLL cells.
TP53
TP53 disruption (both mutation and deletion) is a well characterised poor prognostic marker in CLL (Zenz et al, 2010; Gonzalez et al, 2011) . TP53 abnormalities are common in RS. Rossi et al (2011) found that 47.1% of RS patients displayed TP53 deletion, mutation or both. A similar proportion of patients with TP53 disruption were treated in the prospective CHOP-OR trial . TP53 aberrations have been described in the clonal evolution of CLL to clonally related RS. Rossi et al (2011) reported that of 18 assessable patients with TP53 disruption, the abnormality was acquired at transformation in 10 of these evaluable pairs (55.6%). Moreover, TP53 disruption was significantly more prevalent in clonally related (30 of 50, 60.0%) compared with clonally unrelated RS (3 of 13, 23.1%) (P = 0.018) and was associated with poor prognosis in all RS subgroups. So powerful was the association, that Rossi et al (2011) developed a prognostic scoring system with (i) TP53 disruption included alongside (ii) Eastern Cooperative Oncology Group (ECOG) performance status (PS) and (iii) response to induction therapy.
Similar results were subsequently found in a large genomic study (Chigrinova et al, 2013) . The authors performed highresolution genome-wide DNA array profiling on a large number of samples from CLL and RS patients pre-and posttransformation, and compared them with lone CLL and lone de novo DLBCL. The group showed that TP53 disruption alongside CDKN2A loss are key candidate drivers of transformation, and are present in approximately 50% of RS cases. Most TP53 disruption was present prior to transformation and CDKN2A mutations typically occurred at transformation. They noted a clear association with MYC overexpression and TP53 disruption in some cases; providing a classical oncogenic combination (Xie et al, 2014) . This group again noted that TP53 abnormalities were a poor prognostic marker.
Cytogenetic abnormalities pre-RS in CLL
Chigrinova et al (2013) compared the genomic profiles of patients with CLL who subsequently transformed to RS with those that did not transform at a 6 year follow-up. Using genome-wide array, the preceding CLL phase did not display a higher genomic complexity when compared with CLL cases that did not transform. There were, however, key differences in the frequency of specific cytogenetic abnormalities. The group identified a significantly higher frequency of 17p (TP53) losses, 15q (MGA) losses, and 2p gains (MYCN, REL) and fewer 13q14.3 (MIR15/MIR16) deletions in CLL that subsequently developed RS.
CDKN2A
The cyclin-dependent kinase inhibitor 2A (CDKN2A) gene encodes an isoform that inhibits CDK4 kinase. Together with TP53, CDK4 kinase plays a key regulatory role in cell cycle G1 progression and control. Chigrinova et al (2013) described CDKN2A as a candidate driver of transformation from CLL to DLBCL. Losses at 9p21, where CDKN2A and another 17 genes are located, were the most statistically significant mutation occurring at transformation; detected in up to 20% of RS patients but in no CLL cases without transformation. A number of cases displayed clear acquisition at transformation. CDKN2A losses were associated with MYC activation and/or TP53 inactivation. Additional RB1 losses and gains of MIR17HG were also associated with RS. Combinations of these genetic anomalies were seen in 30 of 60 cases of RS. Patients with TP53/and or CDKN2A inactivation had a significantly worse OS than those without (P = 0.0105; hazard ratio 3.6, 95% CI 1.3-10.1).
NOTCH1
The NOTCH family is a highly conserved group of genes that are critical in regulating haematopoiesis and helping to mediate cell fate and diversity (Burns et al, 2005; Bigas & Espinosa, 2012) . NOTCH1 is a ligand-dependent transcription factor known to be mutated in CLL. Activating somatic mutations in NOTCH1 are associated with a reduced OS in CLL (Del Giudice et al, 2012; Rossi et al, 2012; Villamor et al, 2012) . Patients with a NOTCH1 mutation have been shown to be significantly more likely to transform to RS (45% with NOTCH1 mutations versus 4% without). NOTCH1 mutations are typically associated with trisomy 12, unmutated IGHV and ZAP70 positivity (Balatti et al, 2012; Del Giudice et al, 2012) . The group of RS with trisomy 12 (associated with NOTCH1 mutations) are mutually exclusive from those harbouring TP53/CDKN2A/MYC genetic abnormalities (Chigrinova et al, 2013) .
Targeted next generation sequencing
Recent data from the CHOP-OR clonally related RS trial patients showed that a significant increase in mutation burden was noted by targeted next generation sequencing when comparing the general CLL population, the CLL phase of RS and RS respectively (Stamatopoulos et al, 2016) . This was noted for ATM (15% (n = 81/538), 57% (n = 17/30), 78% (n = 14/18) respectively), TP53 [7% (n = 38/538), 23% (n = 7/30), 56% (n = 10/18)], NOTCH1 [6% (n = 32/538), 23% (n = 7/30), 50% (n = 9/18)], CDKN2A [<1% (n = <5/ 538), 20% (n = 6/30), 50% (n = 9/18)], SAMHD1 [2% (n = 11/538), 13% (n = 4/30), 33% (n = 6/18)], XPO1 [4% (n = 22/538), 7% (n = 2/30), 28% (n = 5/18)] and IRF4 [2% (n = 11/538), 3% (n = 1/30), 28% (n = 5/18)]. The most frequently acquired mutations in the RS phase were TP53 and CDKN2A followed by SAMHD1, XPO1 and MED12. The presence of high-risk mutations in any of the following six genes in the preceding CLL phase (defined here as NOTCH1, SF3B1, SAMHD1, DDX3X, FBXW7, KLHL6) conferred a poor prognosis. Patients with no mutation in these genes had a median progression-free survival (PFS) of 14.9 months compared to patients with at least one mutated gene, who had a median PFS of only 5.3 months (P = 0.0022).
Epstein-Barr virus
Epstein-Barr virus (EBV) is known to drive lymphoproliferation and immunoblastic transformation in B cells (Castillo et al, 2011) , particularly in the immunosuppressed host. The best described association between CLL and EBV in association with DLBCL-type RS is in patients exposed to prior purine analogues (Cohen et al, 2002; Thornton et al, 2005) . It is however unclear whether EBV noted in DLBCL biopsies represents merely a surrogate marker of immunosuppression due to CLL itself and prior chemotherapy, rather than a causative effect. In contrast, a more clear association is reported in cHL-RS where latent membrane protein 1 (LMP1) by IHC or EBV-encoded RNA (EBER) by in-situ hybridisation (ISH) is expressed in up to 70% (Tsimberidou et al, 2006b; Bockorny et al, 2012) . In the CHOP-OR trial, only two of 29 tested cases were positive for EBV by either LMP1 IHC or EBER ISH. Neither had received prior fludarabine and one was treatment-na€ ıve . There is little evidence to suggest an association with EBV in typical DLBCL arising in CLL patients not exposed to prior purine analogues (Rossi et al, 2011) . Clonally unrelated EBV-positive aggressive lymphomas can arise in CLL patients treated with the potent T-cell depleting anti-CD52 monoclonal antibody alemtuzumab, although patients had often also received prior fludarabine Lepretre et al, 2012 ). At present, this possible association remains of diagnostic interest, but has little clinical implications in the management of RS.
Prognostic scoring at RS diagnosis
A retrospective RS cohort from the Mayo Clinic (1995-2013) (Parikh et al, 2013 ) and a separate Italian database (Rossi et al, 2011) both validated a clinical scoring system developed by Tsimberidou et al (2006a) . Adverse risk factors within the scoring system are: 1. PS >1; 2. LDH ≥1.5 times the upper limit of normal; 3. Platelet count <100 9 10 9 /l; 4.
Tumour bulk >5 cm; 5. >1 previous line of chemotherapy for underlying CLL. From this original data set, patients with a score of 4-5 (n = 26) have a median survival of 0.14 years, a score of 3 (n = 19) a survival of 0.33 years, a score of 2 (n = 42) a survival of 0.9 years, compared to those with a score of 0-1 (n = 43) with a survival of 1.1 years (Tsimberidou et al, 2006a; Parikh et al, 2013) . A recent scoring system introduced by Rossi et al (2011) included biological risk factors. The three factors were (i) ECOG PS >1, (ii) less than complete response (CR) to induction immuno-chemotherapy, (iii) presence of TP53 disruption (deletion or mutation). Patients with no risk factors (n = 11 'low risk') in CR post-induction had a 5-year survival of 70%. Those with a ECOG PS >1 (n = 30 'high risk') had a survival of 0.7 years and those with a PS ≤1 with TP53 disruption or less than CR after induction (n = 41 'intermediate risk') had a median survival of 2 years (Rossi et al, 2011) . There is no evidence at present that either of these scoring systems should be used to alter therapy at induction. The CHOP-OR trial attempted to further validate both scoring systems and although analysis was limited by small numbers, the trend of the results were consistent with the prior published data .
Traditional treatment and transplantation
As displayed in Fig 1, patients presenting with RS often have heavily pre-treated CLL, are typically elderly, possess co-morbidities, have a deteriorating ECOG PS at transformation, and underlying immunosuppression. Taken together with the relative chemotherapy resistance of RS, the result of this combination of factors has been a historical median OS of only 8 months (Tsimberidou et al, 2006a) . Even in otherwise fit patients where stem cell transplantation (SCT) consolidation has remained an option, results have generally been disappointing. A number of regimens have been assessed in small phase II studies as detailed in Table I . They have included R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) (Coiffier et al, 2002; Langerbeins et al, 2014) , R-hyper-CVXD-MA (rituximab plus fractionated cyclophosphamide, vincristine, liposomal daunorubicin, dexamethasone, rituximab and alternating methotrexate, cytarabine, rituximab) (Tsimberidou et al, 2003) , hyper-CVXD alone (Dabaja et al, 2001) , FACPGM (fludarabine, cytarabine, cyclophosphamide, cisplatin and granulocyte-macrophage colony-stimulating factor) (Tsimberidou et al, 2002) , OFAR1 (oxaliplatin, fludarabine, cytarabine, rituximab and pegfilgrastim) (Tsimberidou et al, 2008) and OFAR2 (Tsimberidou et al, 2013) (Tsimberidou et al, 2006a) . Overall response rates (ORR) ranged from 5% with FACPGM, 38.7% with OFAR2, 41% with hyper-CVXD and R-hyper-CVXD-MA to 50% with OFAR1. Hyper-CVXD and OFAR demonstrated reasonable ORR, however these regimens are toxic, inappropriate for many patients with RS, and responses are non-durable. This resulted in a poor median OS (median OS was 10 months in the hyper-CVXD cohort, for example). A recent study of 15 patients with RS were treated with R-CHOP (Langerbeins et al, 2014) . Although the ORR was a more encouraging 67%, the study was small and the median PFS remained only 10 months.
A retrospective cohort study evaluated the outcome of patients with RS consolidated with autologous or allogeneic SCT (Cwynarski et al, 2012) . Prior to this publication, data regarding consolidation strategies with autologous or allogeneic SCT in RS were minimal (Rodriguez et al, 2000) . Of the 59 patients in the registry, 34 received an autologous SCT and 25 received an allogeneic SCT. Thirty-six per cent of the patients were chemo-resistant at time of SCT. As expected, patients with chemosensitive disease at SCT had a superior OS to those without. The estimated 3-year OS in those post-autologous SCT was more than 50%, although there was no plateau on the survival curve. This compares favourably to outcomes for chemo-sensitive disease not treated with SCT consolidation (Tsimberidou et al, 2006a) . Unsurprisingly, patients with chemosensitive disease had a superior OS after allogeneic SCT than those with progressive disease (PD). The utility of allogeneic SCT in high-grade lymphoma is controversial. Interestingly, all relapse-free survivors post-allogeneic SCT received reduced intensity conditioning, arguing for the presence of graft-versus-lymphoma effect. No formal international recommendations currently exist regarding the use of SCT in RS and consolidation with SCT remains a reasonable approach in otherwise fit patients with chemosensitive disease in first CR. A summary guide of a standard therapeutic approach is highlighted in Fig 2. The CHOP-OR trial
In the largest (n = 43) prospective multi-centre National Cancer Research Institute non-randomised phase II trial in RS, patients received standard CHOP alongside ofatumumab, an anti-CD20 monoclonal antibody which showed responses as a single agent in relapsed, refractory CLL with relatively minimal toxicity (Wierda et al, 2010) . Ofatumumab is associated with increased CD20 binding affinity and longer dissociation time compared to rituximab (Teeling et al, 2006; Barth et al, 2012) , improving complement-dependent cellular cytotoxicity and therefore potential activity in TP53 disruption. At the time of trial conception, CHOP with ofatumumab maintenance represented a biologically sound and tolerable treatment. Forty-three patients were recruited and 37 were evaluable. Despite the rationale, the ORR was 65% [CR 19% and partial response (PR) 46%] after four cycles of CHOP-O, falling to 46% ORR (CR 27%, PR 19%) at six cycles. The median PFS was 6.2 months (95% CI 4.9-14.0 months) and the median OS was 11.4 months (95% CI 6.4-25.6 months). Within the limitations of a trial with relatively small numbers, this trial showed that chemo-immunotherapy was not effective in RS and that novel therapeutic approaches are urgently required.
Histopathological diagnosis of RS
The CHOP-OR trial pre-specified that an independent, blinded retrospective centralised review of histological material by two designated specialist haematopathologists would be performed following trial completion. Forty of the 43 patients enrolled had material available for central haematopathology review to determine whether the submitted diagnosis of RS was in keeping with the strict WHO criteria (Swerdlow et al, 2008) . Concordance rates between the specialist haematopathologists were recorded. All cases where the specialist haematopathologist opinion initially differed were subsequently reviewed and a consensus reached. Following independent blinded central review and subsequent discussion regarding six cases of initial discordance, consensus was reached in all 40 cases. In their view, 82.5% (33/40) submitted cases demonstrated features consistent with strict WHO criteria. The level of discordance between one or more of the 3 pathologists (initial local pathologist and the two blinded central pathologists) was 30% (12/40). Reasons for diagnostic uncertainty in the discrepant cases included large proliferation centres, variably confluent and serpiginous proliferation centres and cases with an apparently high proliferation index, sometimes due to a thick section or associated proliferating normal bone marrow proliferation (Soilleux et al, 2016) . This experience represented the largest central review of RS within a prospective clinical trial in the literature and has shown that the diagnosis of RS is non-trivial, requires expert haematopathology input and careful evaluation in view of the WHO criteria.
RS in the era of novel CLL therapies
As novel therapies, such as idelalisib, ibrutinib and venetoclax, are successfully trialled in CLL (Byrd et al, 2013; Furman et al, 2014; Roberts et al, 2015) , their use is becoming more prevalent and they are likely to be rapidly brought forward in the treatment pathway of CLL as single agents (Burger et al, 2015) and in combination. Although treatmentna€ ıve patients will continue to transform, it is highly likely that in the future many patients presenting with RS will have often been exposed to B-cell receptor pathway inhibitors, novel monoclonal antibody therapy (Goede et al, 2014) , or BH3 mimetics . As such, the disease biology and genetics of high-grade transformation in this setting will require careful re-evaluation to determine whether similar known mutational drivers are prevalent and important in the pathogenicity. Understanding this may impact future therapeutic directions.
Novel therapies for the future?
As described, clonally related DLBCL RS is a chemo-resistant and devastating disease. It is clear that traditional immunochemotherapy is inadequate when treating clonally related RS. Future clinical trials need to be carefully designed with the aim to target chemo-resistant ABC type DLBCL and the molecular abnormalities driving this transformation. Regimens must be both efficacious and tolerable in the setting of an elderly, co-morbid, pre-treated, immunocompromised population. A number of novel agents are at various stages of development in clinical trials in RS. Table II describes the novel agents recently under investigation in the multi-centre, multi-national setting.
DNA oligonucleotide hybridisation
PNT2258 is a single-stranded liposome-encapsulated DNA oligonucleotide that hybridizes to regions of the BCL2 gene and down regulates its expression. PNT2258 is given at a dose of 120 mg/m 2 intravenously on days 1-5 of a 21-day cycle for 6-8 cycles. Thirteen patients were treated in the (Harb et al, 2014) . No grades 3-4 adverse events were noted in cycle 1. The best responses were seen in the four patients with DLBCL (one of which had RS). Two CRs (including a 79-year-old with RS), one PR and one stable disease (SD) were observed. The patient with RS had previously progressed through R-CVP (rituximab, cyclophosphamide, vincristine and prednisolone) and R-ICE (rituximab, ifosfamide, carboplatin and etoposide). A complete metabolic response (CMR) by FDG PET-CT scan was observed after treatment and clinical benefit was maintained for 288 days (Harb et al, 2014 ). An international phase II study of single agent PNT2258 was set up (NCT02378038), but closed early due to poor recruitment and limited efficacy after only 5 patients were enrolled.
SINE inhibition
Selinexor is an oral selective inhibitor of nuclear export (SINE). This novel mechanism of action results in nuclear retention and subsequent activation of a number of tumour suppressor proteins including TP53, IKB, FOXO and CDKN2A (p21). Selinexor also inhibits nuclear export and translation of oncogenic mRNAs. Preclinical models have shown the ability of the compound to induce apoptosis in T and B cell NHL cell lines. A recent phase 1 study of single agent selinexor observed durable activity in a variety of heavily pre-treated NHL. Two PRs were seen in the six patients with RS in this study (Kuruvilla et al, 2014) . Despite these initial interesting data, a phase II trial (NCT02138786) in relapsed, refractory RS recruited poorly and terminated early.
Bruton tyrosine kinase inhibition
A recent small case series of four patients has demonstrated that Bruton tyrosine kinase (BTK) inhibition with ibrutinib has efficacy in RS (Tsang et al, 2015) . A case report of ibrutinib in combination with rituximab in a similar setting has also displayed activity (Lamar et al, 2015) . Acalabrutinib (ACP-196) is a potent, second generation BTK inhibitor, with highly specific BTK inhibitory activity. Compared with ibrutinib, acalabrutinib has much higher 50% inhibitory concentration (IC 50 ; >1000 nmol/l) or virtually no inhibition on the kinase activities of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC and YES1. Acalabrutinib has no inhibition of platelet activity in vivo. The agent is currently being investigated in a number of lymphoproliferative diseases including CLL, mantle cell lymphoma (NCT02213926) and lymphoplasmacytic lymphoma (N02180724). Single agent acalabrutinib is being assessed in a phase 1b study (ACE-CL-001 trial (NCT02029443)) with multiple treatment arms, including a RS arm. The monotherapy efficacy demonstrated in the interim results of the phase Ib arm treating relapsed, refractory CLL at 100 mg b.d. until progression or toxicity is remarkable . The 95% ORR [85% PR and 10% PR with lymphocytosis (PR-L)] at a median follow-up of 14.3 months in patients with relapsed/refractory CLL (n = 60 evaluable) demonstrated the potential for acalabrutinib to become an excellent therapeutic option for relapsed, refractory CLL. Notably, a 100% ORR was achieved for those patients that were positive for the TP53 disruption. Twenty-nine patients were recruited into the RS-specific arm of the ACE-CL-001 trial and received acalabrutinib at 200 mg b.d. until disease progression or intolerable toxicity . The median age of the cohort was 66 years (range 43-82 years). The median time from initial diagnosis was 5 years (range 1-21 years) and the cohort was heavily pre-treated with a median number of prior therapies for either CLL or RS of 4 (range 0-13 therapies). Fourteen patients (48%) had received prior ibrutinib. Twenty-seven per cent (7/26) were TP53 disrupted and 81% (13/16) had an unmutated IGHV gene.
Treatment was typically well tolerated with only a single treatment-related grade 3 event (anaemia). No patients discontinued acalabrutinib due to toxicity and there were no unexpected side effects. The most common drug-related adverse events were headache [grades 1-2 in 35% (n = 10)], diarrhoea [grades 1-2 in 21% (n = 6)] and anaemia [grades 1-2 in 14% (n = 4)]. In the efficacy evaluable population (n = 21), the ORR was an encouraging 38% (95% CI 18.1-61.6%), including CR in 3 (14%) and PR in 5 (24%) patients. Among eight responders (PR or better) the median duration of response was 5.7 months (95% CI, 0.3-7.5 months) and the median time to response was 1.8 months (95% CI, 1.4-2.1 months). The median time on treatment for the whole cohort to date was 3.4 months (range 1.7-12.0 months). Two patients in CR went on to receive an allogeneic SCT of whom a single patient remains in remission post-engraftment having temporarily withheld the acalabrutinib peri-SCT. Among 6 efficacy evaluable patients who previously received ibrutinib, three responded (PR or better) to acalabrutinib. These preliminary data demonstrates that acalabrutinib has very promising singleagent activity in RS patients and efforts are underway to further evaluate the agent in a formal randomised phase II trial.
Checkpoint pathway inhibition
Preliminary data presented at the ASH meeting in 2015 suggests some clinical activity of pembrolizumab , an anti-programmed cell death (PD)-1 (also termed PDCD1) IgG monoclonal antibody, which activates innate Tcell anti-tumour immunity (Eyre & Collins, 2015) . Seven patients were treated with single agent pembrolizumab with some early encouraging clinical responses . These data were updated (Ding et al, 2016) with one CR (11%), three PR (33%), three SD (33%) and two PD (22%) in nine RT patients treated (NCT02576990). In the four responding patients, responses occurred early after 2 cycles of 3-weekly pembrolizumab and the median duration of Early results describing the clinical trial (NCT02420912) experience of nivolumab in RS were presented at the 2016 ASH meeting (Jain et al, 2016) . Five patients with RS in cohort 1 were treated with a single month of 2-weekly nivolumab therapy followed by the additional of ibrutinib after that time. Nivolumab was planned for up to 2 years alongside ibrutinib in patients responding with tolerable toxicity. Data from three patients was presented with early responses (CMR n = 2; partial metabolic response n = 1) to nivolumab. No grades 3-4 adverse events were documented. These data are immature and it remains very much an open question as to whether checkpoint inhibition will be an effect primary treatment or adjunctive therapy in RS. Correlative studies with PD1 and PD-L1 (CD274) expression are ongoing, but based on these small patient numbers it seems unlikely that definitive evidence for a correlative effect of PD1/PDL-1 expression and response will be possible in these cohorts.
Other potential candidate drugs
Lenalidomide has shown activity in ABC type DLBCL and in TP53-disrupted CLL (B€ uhler et al, 2016) . It is safe and effective in combination with R-CHOP for treating de novo DLBCL (particularly ABC-type) in phase I-II studies (Nowakowski et al, 2014; Vitolo et al, 2014) .
Potent Cyclin-Dependent Kinase 4 (CDK4) inhibitors are in development in pre-clinical (Young et al, 2014) and clinical studies. CDK4 inhibitors perform the function of the otherwise poorly expressed CDKN2A gene and help regulate cell cycle G1 progression and control. Given the importance of CDK4 in tumourigenesis across a range of cancers (Nobori et al, 1994) these agents have the potential for widespread applicability. Recent studies suggest that the CDK4 inhibitor PD0332991 is safe and efficacious in mantle cell lymphoma and liposarcoma (Leonard et al, 2012; Dickson et al, 2013) .
Richter syndrome patients with activating NOTCH1 somatic mutations could be offered NOTCH inhibition alongside immuno-chemotherapy. One of the initiating steps in the activation of the NOTCH pathway is mediated by gamma-secretase, a proteolytic enzyme which produces activated intracellular Notch. Agents such as RO4929097 and MK-0752 are gamma secretase inhibitors that result in the blockade of NOTCH signalling. Both are currently proceeding through early phase trials in solid tumours (Krop et al, 2012; Strosberg et al, 2012; Tolcher et al, 2012; Richter et al, 2013) .
Conclusion
Rapid advances in molecular diagnostics, together with the development of a number of novel small molecule inhibitors, immunomodulators, BH3 mimetics and monoclonal antibodies, has led to a paradigm shift in the treatment pathways in CLL. Given the overall responses rates of standard immunochemotherapy in RS, novel treatments are required. One of the promising agents at present is acalabrutinib and further efforts to investigate its efficacy both as a single agent and in combination are ongoing. Further data with regards to checkpoint inhibition in RS is also eagerly awaited.
Integrating both 'real-time' molecular diagnostics and novel, targeted combination regimens has promised to improve clinical outcomes. To test the validity of such an approach in a rare disease, well organised, multi-centre, carefully designed clinical trials are needed. The rarity of RS highlights the critical importance of national and international collaborative efforts to ensure feasibility of molecularly directed clinical trials to improve outcomes for our patients in the future.
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